Certara (NASDAQ:CERT) Releases Earnings Results, Beats Expectations By $0.03 EPS

Certara (NASDAQ:CERT) announced its earnings results on Thursday. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03, FiscalAI reports. The business had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. Certara had a return on equity of 5.17% and a net margin of 2.62%.During the same period in the prior year, the business posted $0.13 earnings per share. Certara updated its FY 2025 guidance to 0.450-0.470 EPS.

Certara Stock Down 23.1%

Shares of NASDAQ CERT traded down $2.60 during mid-day trading on Friday, reaching $8.67. The company had a trading volume of 9,104,388 shares, compared to its average volume of 1,604,633. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. Certara has a twelve month low of $8.47 and a twelve month high of $15.69. The stock’s 50 day moving average is $11.77 and its 200-day moving average is $11.51. The stock has a market capitalization of $1.39 billion, a PE ratio of 123.86 and a beta of 1.44.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the transaction, the insider directly owned 73,979 shares of the company’s stock, valued at $807,850.68. This represents a 40.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Certara

Several institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. raised its position in Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after acquiring an additional 1,165,064 shares in the last quarter. First Trust Advisors LP grew its position in Certara by 3,000.6% in the second quarter. First Trust Advisors LP now owns 394,924 shares of the company’s stock worth $4,621,000 after acquiring an additional 382,187 shares in the last quarter. Public Sector Pension Investment Board increased its stake in shares of Certara by 8.3% during the 2nd quarter. Public Sector Pension Investment Board now owns 376,100 shares of the company’s stock worth $4,400,000 after purchasing an additional 28,924 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after purchasing an additional 35,954 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock valued at $2,743,000 after purchasing an additional 40,463 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CERT has been the subject of several recent analyst reports. Craig Hallum initiated coverage on shares of Certara in a report on Monday, September 29th. They issued a “buy” rating and a $16.00 target price for the company. UBS Group reduced their price target on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a research report on Thursday, August 7th. Barclays decreased their price objective on shares of Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Certara in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Certara from a “hold” rating to a “buy” rating in a research report on Saturday. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara has a consensus rating of “Hold” and an average price target of $15.38.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.